Další formáty:
BibTeX
LaTeX
RIS
@article{970699,
author = {Volejníková, Jana and Mejstříková, Ester and Valova, Tatana and Reznickova, Leona and Hodonska, Ladislava and Mihal, Vladimir and Štěrba, Jaroslav and Jabali, Yahia and Prochazkova, Daniela and Blazek, Bohumir and Hak, Jiri and Cerna, Zdenka and Hrusak, Ondrej and Stary, Jan and Trka, Jan and Fronkova, Eva},
article_location = {Italy},
article_number = {12},
doi = {http://dx.doi.org/10.3324/haematol.2011.042937},
keywords = {acute lymphoblastic leukemia; peripheral blood; minimal residual disease; day 15; childhood},
language = {eng},
issn = {0390-6078},
journal = {Hematologica - The Hematology Journal},
title = {Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell presursor acute lymphoblastic leukemia with superior prognosis.},
volume = {96},
year = {2011}
}
TY - JOUR
ID - 970699
AU - Volejníková, Jana - Mejstříková, Ester - Valova, Tatana - Reznickova, Leona - Hodonska, Ladislava - Mihal, Vladimir - Štěrba, Jaroslav - Jabali, Yahia - Prochazkova, Daniela - Blazek, Bohumir - Hak, Jiri - Cerna, Zdenka - Hrusak, Ondrej - Stary, Jan - Trka, Jan - Fronkova, Eva
PY - 2011
TI - Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell presursor acute lymphoblastic leukemia with superior prognosis.
JF - Hematologica - The Hematology Journal
VL - 96
IS - 12
SP - 1815-1821
EP - 1815-1821
SN - 03906078
KW - acute lymphoblastic leukemia
KW - peripheral blood
KW - minimal residual disease
KW - day 15
KW - childhood
N2 - Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction. Design and Methods In this study, we employed real-time quantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol. Results We confirmed the previously published poor correlation between minimal residual disease in blood and marrow at early treatment time points, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold, range 0.04-8,293-fold). A greater involvement of peripheral blood at diagnosis was associated with a higher white blood cell count at diagnosis (P=0.003) and with enlargement of the spleen (P=0.0004) and liver (P=0.05). At day 15, a level of minimal residual disease in blood lower than 10(-4) was associated with an excellent 5-year relapse-free survival in 78 investigated patients (100% versus 69 +/- 7%; P=0.0003). Subgroups defined by the level of minimal residual disease in blood at day 15 (high-risk: >= 10(-2), intermediate-risk: <10(-2) and >= 10(-4), standard-risk: <10(-4)) partially correlated with bone marrow-based stratification described previously, but the risk groups did not match completely. No other time point analyses were predictive of outcome in peripheral blood, except for a weak association at day 8. Conclusions Minimal residual disease in peripheral blood at day 15 identified a large group of patients with an excellent prognosis and added prognostic information to the risk stratification based on minimal residual disease at day 33 and week 12.
ER -
VOLEJNÍKOVÁ, Jana, Ester MEJSTŘÍKOVÁ, Tatana VALOVA, Leona REZNICKOVA, Ladislava HODONSKA, Vladimir MIHAL, Jaroslav ŠTĚRBA, Yahia JABALI, Daniela PROCHAZKOVA, Bohumir BLAZEK, Jiri HAK, Zdenka CERNA, Ondrej HRUSAK, Jan STARY, Jan TRKA a Eva FRONKOVA. Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell presursor acute lymphoblastic leukemia with superior prognosis. \textit{Hematologica - The Hematology Journal}. Italy, 2011, roč.~96, č.~12, s.~1815-1821. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2011.042937.
|
